«

»

Oct 30

2nd Annual Berthiaume Institute for Precision Health’s Advisory Board Meeting

Categories:

antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, Biomedical Imaging, Combination chemotherapy, Label-free, magnetoelectrics, multidrug resistance

by Prakash

Kevin (L) and Conor (R) presenting their work on phage-mimicking antibacterial nanoparticles
Carlie presenting the in vivo results of MagSiNs-Dox targeted to breast cancer tumors in mice models.
Kevin and Conor expounding the advantages of phage-mimicking nanoparticles to Dr.Enid Gatimu (Forma Therapeutics)
Carlie explaining to Dr. Thomas (Chief NextGen seq- Walter Reed) the in vivo results of Doxorubicin delivery to triple negative breast cancer tumors in mice by Dox-MagSiNs.

Great job by the Nallathamby lab (PDNANO) members Conor, Kevin and Carlie at presenting our work on antibacterials, and cancer therapeutics to the @ND_IPH advisory board! Great input from the advisory board members on possible collaborations and translational paths forward. #GoIrish#NDResearch#MDR#curecancer

All three presenters have publications with us which formed the basis for these poster presentations.

Publications with us:
1. Nanoscale Adv., 2019,1, 4812-4826

2. Pharmaceuticals 2022, 15, 1216. https://doi.org/10.3390/ph15101216

3. Nanoscale Advances, 2024, DOI: 10.1039/D3NA00620D

This post has no tag